Tharimmune Management

Management criteria checks 3/4

Tharimmune's CEO is Randy Milby, appointed in Jan 2017, has a tenure of 7.33 years. total yearly compensation is $742.42K, comprised of 50.5% salary and 49.5% bonuses, including company stock and options. directly owns 1.33% of the company’s shares, worth $58.07K. The average tenure of the management team and the board of directors is 2.9 years and 2.8 years respectively.

Key information

Randy Milby

Chief executive officer

US$742.4k

Total compensation

CEO salary percentage	50.5%
CEO tenure	7.3yrs
CEO ownership	1.3%
Management average tenure	2.9yrs
Board average tenure	2.8yrs

Recent management updates

Recent updates

Is Hillstream BioPharma (NASDAQ:HILS) In A Good Position To Invest In Growth?

Feb 14

CEO Compensation Analysis

How has Randy Milby's remuneration changed compared to Tharimmune's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	-US$9m
Dec 31 2023	US$742k	US$375k	-US$9m
Sep 30 2023	n/a	n/a	-US$9m
Jun 30 2023	n/a	n/a	-US$9m
Mar 31 2023	n/a	n/a	-US$8m
Dec 31 2022	US$3m	US$472k	-US$8m
Sep 30 2022	n/a	n/a	-US$4m
Jun 30 2022	n/a	n/a	-US$3m
Mar 31 2022	n/a	n/a	-US$3m
Dec 31 2021	US$973k	n/a	-US$2m
Sep 30 2021	n/a	n/a	-US$6m
Jun 30 2021	n/a	n/a	-US$6m
Mar 31 2021	n/a	n/a	-US$4m
Dec 31 2020	US$194k	n/a	-US$2m

Compensation vs Market: Randy's total compensation ($USD742.42K) is about average for companies of similar size in the US market ($USD664.85K).

Compensation vs Earnings: Randy's compensation has been consistent with company performance over the past year.

CEO

Randy Milby (69 yo)

7.3yrs

Tenure

US$742,415

Compensation

Mr. Randy D. Milby, MBA is the Chairman and Chief Executive Officer of Tharimmune, Inc. (formerly known as Hillstream BioPharma, Inc.) since 2017. He is President at Tharimmune, Inc. (formerly known as Hil...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Randy Milby	President	7.3yrs	US$742.42k	1.33% $ 58.1k
Sireesh Appajosyula	COO & Director	less than a year	US$602.16k	0.43% $ 18.6k
Thomas Hess	Chief Financial Officer	2.9yrs	no data	no data

2.9yrs

Average Tenure

59yo

Average Age

Experienced Management: THAR's management team is considered experienced (2.9 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Randy Milby	President	7.3yrs	US$742.42k	1.33% $ 58.1k
Sireesh Appajosyula	COO & Director	2.8yrs	US$602.16k	0.43% $ 18.6k
Donald W. Kufe	Chair of the Scientific Advisory Board	no data	no data	no data
Leonard Mazur	Independent Director	2.8yrs	US$34.43k	0.042% $ 1.8k
Kelly Anderson	Independent Director	less than a year	US$46.17k	0% $ 0
Kwok-Kin Wong	Member of Scientific Advisory Board	no data	no data	no data
Richard Stone	Member of Scientific Advisory Board	no data	no data	no data
Joseph Eder	Member of Scientific Advisory Board	no data	no data	no data
Paul Richardson	Member of Scientific Advisory Board	no data	no data	no data
Lynne Bui	Independent Director	2.8yrs	US$41.57k	0% $ 0
Scott Dixon	Member of Scientific Advisory Board	no data	no data	no data
Jonathan Rayner	Member of Scientific Advisory Board	no data	no data	no data

2.8yrs

Average Tenure

62yo

Average Age

Experienced Board: THAR's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

Tharimmune Management

Management criteria checks 3/4

Key information

Recent management updates

Tharimmune, Inc., Annual General Meeting, May 14, 2024

Less than half of directors are independent

Hillstream BioPharma, Inc., Annual General Meeting, Aug 08, 2022

No independent directors

Recent updates

Tharimmune, Inc., Annual General Meeting, May 14, 2024

Tharimmune, Inc. Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate

Tharimmune, Inc. Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis

Tharimmune, Inc. Announces Initiation of Phase 1 Clinical Trial of TH104

Tharimmune, Inc. Announces Positive Topline Data with Th104, Its Lead Candidate for Moderate-To-Severe Pruritus in Chronic Liver Disease Patients

Tharimmune Reports Positive Phase 1 Data on Th104, Its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis (Pbc)

Tharimmune, Inc. has completed a Follow-on Equity Offering.

Tharimmune Receives a Letter from the Listing Qualifications Staff of the Nasdaq Stock Market

Tharimmune, Inc. has filed a Follow-on Equity Offering.

Hillstream Biopharma Progressing Towards Acquiring Clinical Stage Asset

New major risk - Shareholder dilution

Less than half of directors are independent

Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2 HER3 Solid Tumors Via Bispecific and ADC Antibodies and Biologics

Hillstream Biopharma Receives Written Notice from Nasdaq Regarding Minimum Bid Price Requirement

Hillstream BioPharma, Inc. announced delayed 10-Q filing

Hillstream BioPharma Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

Is Hillstream BioPharma (NASDAQ:HILS) In A Good Position To Invest In Growth?

Hillstream BioPharma, Inc. Announces Initial Results Evaluating the Synergy

Hillstream BioPharma, Inc. Announces Acceptance of Abstract At AACR 2023 Annual Meeting Highlighting HSB-510 as Novel Bi-Functional Inhibitor for Solid Tumors & Leukemias

Hillstream BioPharma, Inc. to Host Virtual R&D Day to Showcase Its Emerging Immuno-Oncology Pipeline Targeting Drug-Resistant Cancers

Hillstream BioPharma Receives Non-Compliance Written Notice from the Nasdaq

Hillstream BioPharma, Inc., Annual General Meeting, Aug 08, 2022

Hillstream BioPharma, Inc. (NasdaqCM:HILS) announces an Equity Buyback for $1 million worth of its shares.

Hillstream BioPharma, Inc. announced delayed annual 10-K filing

Hillstream BioPharma, Inc. has completed an IPO in the amount of $15 million.

No independent directors

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age